Status:

UNKNOWN

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies

Lead Sponsor:

Metronome Therapeutics

Conditions:

Nonhematologic Malignancies

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for...

Eligibility Criteria

Inclusion

  • capable of understanding study requirements and able to provide Informed Consent
  • diagnosed with a non-hematologic malignancy for which there are no currently accepted therapies
  • life expectancy at least 3 months
  • agreement to use medically acceptable contraception throughout the study
  • willing and able to comply with the protocol requirements

Exclusion

  • currently receiving systemic treatment for malignancy
  • not yet recovered from the toxicity of prior therapies
  • platelet count \< 100,000 cells/mm3 within 7 days prior to study entry
  • ANC \< 1500 cells/mm3 within 7 days prior to study entry
  • hemoglobin \< 8.5 g/dL within 7 days prior to study entry
  • AST and/or ALT \> 2.5 X ULN within 7 days prior to study entry
  • total bilirubin \> 1.5 X ULN within 7 days prior to study entry
  • creatinine clearance \< 60 mL/min (Cockroft-Gault formula) within 7 days prior to study entry
  • receipt of any investigational therapy within 3 weeks prior to study entry
  • known history of HIV, HBV, and/or HCV infection
  • clinically relevant active infection or serious co-morbid medical condition at study entry
  • major surgery within 4 weeks prior to study entry
  • other malignancy within 3 year prior to study entry
  • pregnant or breast-feeding
  • presence of a concomitant disease or condition which, in the opinion of the Investigator, could interfere with the conduct of the study or could put the subject at unacceptable risk

Key Trial Info

Start Date :

March 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 1 2008

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00641160

Start Date

March 1 2008

End Date

November 1 2008

Last Update

September 26 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Texas Oncology PA; Sammons Cancer Center

Dallas, Texas, United States, 75246

Safety Study of Oral Vinorelbine in Subjects With Non-Hematologic Malignancies | DecenTrialz